e-therapeutics plc

("e-therapeutics" or the "Company")

Senior Management Update

Oxford, UK, 22 November 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, regrets to announce that Karl Keegan will step down from his role as CFO (non-board) to focus in the near term on extremely difficult family circumstances in Ireland.  This will take effect from 31 December 2021. The Company is actively looking for a new CFO, during which time Michael Bretherton, a Non-Executive Director of the Company, will act as interim CFO.  The Company will update the market accordingly.

Michael has been a director of seven other AIM quoted companies during the last ten years, including DeepMatter Group Plc, Nanoco Group Plc, Ceres Power Holdings Plc and Tissue Regenix Group Plc. He has a degree in Economics from Leeds University and is a member of the Institute of Chartered Accountants in England and Wales. His early career included working as an accountant and manager with PriceWaterhouse for seven years in London and the Middle East.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "We are very saddened that Karl will be leaving e-therapeutics under these circumstances at the end of the year. We are grateful to Karl for his contribution to e-therapeutics and wish him the very best in the future." 

Enquiries:

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity. 

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology. 

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.